Genfleet Therapeutics (Shanghai), Inc. Class H

As of December 31, 2025, Genfleet Therapeutics (Shanghai), Inc. Class H carries a market capitalization of 8.81B, placing it among publicly traded companies globally. Its enterprise value stands at 6.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genfleet Therapeutics (Shanghai), Inc. Class H's next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Genfleet Therapeutics (Shanghai), Inc. Class H has 370.37M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Genfleet Therapeutics (Shanghai), Inc. Class H maintains a current ratio of 5.85, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Genfleet Therapeutics (Shanghai), Inc. Class H's stock has gained approximately 0.74% over the past 52 weeks. The 50-day moving average sits at 29.32, while the 200-day moving average is 31.75.

As of December 31, 2025, Genfleet Therapeutics (Shanghai), Inc. Class H holds 2.31B in cash and equivalents against 112.31M in total debt, resulting in a net debt position of -1.24B. Total book value stands at 2.02B, with working capital of 1.99B providing operational flexibility.